VistaGen Therapeutics (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company focused on developing new generation therapies for depression and other central nervous system (CNS) disorders. VistaGen’s lead CNS product candidate, AV-101, is an orally available prodrug in Phase 2 development, initially for the adjunctive treatment of
AV-101 is being evaluated in an ongoing Phase 2 monotherapy study in MDD, a study being conducted at the U.S. National Institute of Mental Health (NIMH) and being funded by the NIMH, and expected to conclude by the end of 2017. VistaGen is also preparing to launch a Phase 2 study of AV-101 in the first half of 2017 for the adjunctive treatment of MDD.
Jenene Thomas Communications, LLC
VistaGen Therapeutics, Inc.
Vice President, Corporate Development
Mark A. McPartland
P.O. BOX 30170
College Station, TX 77842